Michael Schweizer, MD, of the University of Washington and Fred Hutchinson Cancer Center, discusses findings from a randomized dose-expansion study of the investigational EZH2 inhibitor mevrometostat in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA138).
Karim Fizazi, MD, PhD, of Institut Gustave Roussy, University of Paris-Saclay, reviews final overall survival results from cohort 2 of the phase III TALAPRO-2 trial, which investigated the combination of talazoparib and enzalutamide in patients with homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (mCRPC) (Abstract LBA141).
William Aronson, MD, of the VA Greater Los Angeles Healthcare System, discusses findings from the CAPFISH-3 trial, which investigated whether a high omega-3, low omega-6 fatty acid diet with fish oil capsules decreased Ki-67 levels in men with prostate cancer on active surveillance (Abstract 312).
Nicholas D. James, PhD, FRCP, MBBS, of The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, discusses findings from an embedded phase II randomized study from the STAMPEDE trial. The study assessed the efficacy and toxicity of transdermal estradiol patches vs luteinizing hormone–releasing hormone analogs in patients with M1 prostate cancer (Abstract 21).
Omid Yazdanpanah, MD, of the University of California, Irvine, presents findings from a secondary analysis of the VISION trial, which compared the efficacy and safety of LuPSMA in patients treated with vs without concomitant androgen receptor pathway inhibitors (ARPIs) (Abstract 121).
Benjamin Maughan, MD, PharmD, of Huntsman Cancer Institute, discusses the effects of a 12-week, structured, guided exercise program called Personal Optimism With Exercise Recovery (POWER) on fatigue and peak aerobic exercise capacity in patients with advanced prostate cancer receiving androgen-deprivation therapy (Abstract 120).
